Is Haemonetics Stock a Good Investment?

Haemonetics Investment Advice

HAE

To provide specific investment advice or recommendations on Haemonetics stock, we recommend investors consider the following general factors when evaluating Haemonetics. This will help you to make an informed decision on whether to include Haemonetics in one of your diversified portfolios:

Examine Haemonetics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Haemonetics' leadership team and their track record. Good management can help Haemonetics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Haemonetics' business and its evolving consumer preferences.
Compare Haemonetics' performance and market position to its competitors. Analyze how Haemonetics is positioned in terms of product offerings, innovation, and market share.
Check if Haemonetics pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Haemonetics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Haemonetics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Haemonetics is a good investment.

Sell

Buy

Hold

Macroaxis provides investment recommendation on Haemonetics to complement and cross-verify current analyst consensus on Haemonetics. Our trade recommendations engine determines the entity's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. To make sure Haemonetics is not overpriced, please check out all Haemonetics fundamentals, including its number of shares shorted, revenue, and the relationship between the shares owned by insiders and price to book . Given that Haemonetics has a price to earning of 50.35 X, we strongly advise you to confirm Haemonetics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Market Performance	Modest	Details
Volatility	Very steady	Details
Hype Condition	Over hyped	Details
Current Valuation	Undervalued	Details
Odds Of Distress	Low	Details
Economic Sensitivity	Almost mirrors the market	Details
Investor Sentiment	Impartial	Details
Analyst Consensus	Strong Buy	Details
Financial Strenth (F Score)	Healthy	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unlikely Manipulator	Details

Examine Haemonetics Stock

Researching Haemonetics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The book value of Haemonetics was currently reported as 17.44. The company has Price/Earnings To Growth (PEG) ratio of 1.55. Haemonetics had not issued any dividends in recent years. The entity had 2:1 split on the 3rd of December 2012.

To determine if Haemonetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Haemonetics' research are outlined below:

	Over 99.0% of the company shares are owned by institutional investors
	Latest headline from zacks.com: MDT Stock Gains From FDA Approval for Its InPen App

Haemonetics Quarterly Liabilities And Stockholders Equity

2.53 Billion

Haemonetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Haemonetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Haemonetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	8th of February 2024 Upcoming Quarterly Report	View
	9th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	9th of May 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of March 2023 Last Financial Announcement	View

Earnings surprises can significantly impact Haemonetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Haemonetics' investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2003-07-24	2003-06-30	0.1	0.11	0.01	10
1999-10-28	1999-09-30	0.1	0.11	0.01	10
1999-01-29	1998-12-31	0.1	0.09	-0.01	10
2004-07-29	2004-06-30	0.17	0.19	0.02	11
2004-05-03	2004-03-31	0.17	0.19	0.02	11
2004-01-22	2003-12-31	0.17	0.19	0.02	11
2003-10-23	2003-09-30	0.13	0.15	0.02	15
2001-01-25	2000-12-31	0.15	0.17	0.02	13

Know Haemonetics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Haemonetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Haemonetics backward and forwards among themselves. Haemonetics' institutional investor refers to the entity that pools money to purchase Haemonetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Schroder Investment Management Group	2024-06-30	925.6 K
Morgan Stanley - Brokerage Accounts	2024-06-30	834 K
Westfield Capital Management Company, Lp	2024-09-30	823.7 K
Btim Corp	2024-09-30	809.6 K
Royal Bank Of Canada	2024-06-30	791.7 K
Fmr Inc	2024-09-30	774.5 K
Fisher Asset Management, Llc	2024-09-30	689.5 K
Franklin Resources Inc	2024-09-30	682 K
Sg Capital Management, Llc	2024-09-30	643.4 K
Blackrock Inc	2024-06-30	6 M
Vanguard Group Inc	2024-09-30	5.2 M

Note, although Haemonetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Haemonetics' market capitalization trends

The company currently falls under 'Mid-Cap' category with a total capitalization of 4.3 B.

Market Cap

1.67 Billion

Haemonetics' profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	0.10	0.05
Return On Capital Employed	0.09	0.07
Return On Assets	0.05	0.04
Return On Equity	0.12	0.06

The company has Net Profit Margin of 0.09 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.16 %, which entails that for every 100 dollars of revenue, it generated $0.16 of operating income.

Determining Haemonetics' profitability involves analyzing its financial statements and using various financial metrics to determine if Haemonetics is a good buy. For example, gross profit margin measures Haemonetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Haemonetics' profitability and make more informed investment decisions.

Haemonetics' Earnings Breakdown by Geography

Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.

Evaluate Haemonetics' management efficiency

Haemonetics has Return on Asset of 0.0588 % which means that on every $100 spent on assets, it made $0.0588 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1397 %, implying that it generated $0.1397 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to 0.05. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 99.5 M, whereas Total Current Assets are forecasted to decline to about 437.2 M.

	Last Reported	Projected for Next Year
Book Value Per Share	18.93	14.26
Tangible Book Value Per Share	(0.22)	7.29
Enterprise Value Over EBITDA	18.91	25.70
Price Book Value Ratio	4.51	5.13
Enterprise Value Multiple	18.91	25.70
Price Fair Value	4.51	5.13
Enterprise Value	1.4 B	1.5 B

Evaluating the management effectiveness of Haemonetics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Haemonetics Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.

Beta

0.321

Basic technical analysis of Haemonetics Stock

As of the 25th of November, Haemonetics retains the Risk Adjusted Performance of 0.0817, market risk adjusted performance of 0.2183, and Downside Deviation of 1.51. Haemonetics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Haemonetics information ratio, value at risk, and the relationship between the standard deviation and treynor ratio to decide if Haemonetics is priced fairly, providing market reflects its last-minute price of 88.46 per share. Given that Haemonetics has jensen alpha of 0.0848, we strongly advise you to confirm Haemonetics's regular market performance to make sure the company can sustain itself at a future point.

Haemonetics' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Haemonetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Haemonetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Haemonetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Stewart Strong over three weeks ago Acquisition by Stewart Strong of 6313 shares of Haemonetics at 95.73 subject to Rule 16b-3
		Josep Llorens over a month ago Disposition of 320 shares by Josep Llorens of Haemonetics at 95.73 subject to Rule 16b-3
		Laurie Miller over two months ago Disposition of 238 shares by Laurie Miller of Haemonetics at 76.54 subject to Rule 16b-3
		Laurie Miller over two months ago Acquisition by Laurie Miller of 2089 shares of Haemonetics subject to Rule 16b-3
		Anila Lingamneni over two months ago Disposition of tradable shares by Anila Lingamneni of Haemonetics at 90.0 subject to Rule 16b-3
		Simon, Christopher over two months ago Disposition of 704 shares by Simon, Christopher of Haemonetics at 75.56 subject to Rule 16b-3
		Anila Lingamneni over six months ago Disposition of 337 shares by Anila Lingamneni of Haemonetics at 96.49 subject to Rule 16b-3
		James Darecca over six months ago Disposition of 432 shares by James Darecca of Haemonetics at 93.33 subject to Rule 16b-3
		Michelle Basil over six months ago Acquisition by Michelle Basil of 9502 shares of Haemonetics at 89.16 subject to Rule 16b-3
		Anila Lingamneni over six months ago Disposition of 184 shares by Anila Lingamneni of Haemonetics at 84.88 subject to Rule 16b-3
		Stewart Strong over six months ago Acquisition by Stewart Strong of 2803 shares of Haemonetics subject to Rule 16b-3
		Jonathan White over a year ago Acquisition by Jonathan White of 25000 shares of Haemonetics subject to Rule 16b-3

Haemonetics' Outstanding Corporate Bonds

Haemonetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Haemonetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Haemonetics bonds can be classified according to their maturity, which is the date when Haemonetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Boeing Co 2196 Corp Bond US097023DG73	View
	HSBC Holdings PLC Corp Bond US404280DR76	View
	MGM Resorts International Corp Bond US552953CD18	View
	AerCap Global Aviation Corp Bond US00773HAA59	View

View All Haemonetics Corporate Bonds

Understand Haemonetics' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Haemonetics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.0817
	Market Risk Adjusted Performance	0.2183
	Mean Deviation	1.44
	Semi Deviation	1.37
	Downside Deviation	1.51
	Coefficient Of Variation	1018.88
	Standard Deviation	2.16
	Variance	4.66
	Information Ratio	0.0375
	Jensen Alpha	0.0848
	Total Risk Alpha	(0.14)
	Sortino Ratio	0.0537
	Treynor Ratio	0.2083
	Maximum Drawdown	14.5
	Value At Risk	(2.10)
	Potential Upside	4.24
	Downside Variance	2.28
	Semi Variance	1.87
	Expected Short fall	(1.69)
	Skewness	2.02
	Kurtosis	7.79

	Risk Adjusted Performance	0.0817
	Market Risk Adjusted Performance	0.2183
	Mean Deviation	1.44
	Semi Deviation	1.37
	Downside Deviation	1.51
	Coefficient Of Variation	1018.88
	Standard Deviation	2.16
	Variance	4.66
	Information Ratio	0.0375
	Jensen Alpha	0.0848
	Total Risk Alpha	(0.14)
	Sortino Ratio	0.0537
	Treynor Ratio	0.2083
	Maximum Drawdown	14.5
	Value At Risk	(2.10)
	Potential Upside	4.24
	Downside Variance	2.28
	Semi Variance	1.87
	Expected Short fall	(1.69)
	Skewness	2.02
	Kurtosis	7.79

Consider Haemonetics' intraday indicators

Haemonetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Haemonetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	16767.75
	Daily Balance Of Power	0.9417
	Rate Of Daily Change	1.03
	Day Median Price	87.78
	Day Typical Price	88.0
	Price Action Indicator	2.14
	Period Momentum Indicator	2.91
	Relative Strength Index	76.98

Haemonetics Corporate Filings

13A	14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934	View Verify
13A	12th of November 2024 An amended filing to the original Schedule 13G	View Verify
8K	7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about	View Verify
F4	5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify

Haemonetics time-series forecasting models is one of many Haemonetics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Haemonetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Haemonetics Stock media impact

Far too much social signal, news, headlines, and media speculation about Haemonetics that are available to investors today. That information is available publicly through Haemonetics media outlets and privately through word of mouth or via Haemonetics internal channels. However, regardless of the origin, that massive amount of Haemonetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Haemonetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Haemonetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Haemonetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Haemonetics alpha.

Haemonetics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Haemonetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Haemonetics Corporate Directors

Robert Abernathy	Independent Director	Profile
Claire Pomeroy	Independent Director	Profile
Catherine Burzik	Independent Director	Profile
Mark Kroll	Independent Director	Profile

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports: